Masimo reports Q4 adjusted EPS $1.80, consensus $1.42

Reports Q4 revenue $600.7M, consensus $593.35M. Katie Szyman, Chief Executive Officer of Masimo (MASI), said “I am extremely excited about the opportunity to lead such an innovative organization as we refocus on our core healthcare business. There are numerous unmet clinical needs that we are well-positioned to address and we have strong momentum behind us. I look forward to interfacing with our customers and discussing our differentiated solutions for patient care. Our 2024 results clearly demonstrate the strong growth and earnings power of our healthcare business. We had a record year in terms of gaining share through customer contracts. As a result of our strategic realignment efforts in the fourth quarter, we expect to see increased earnings and cash flow in 2025 and beyond.”